ישראל -
עברית -
Ministry of Health
אפרקס מזרקים 3000
j-c health care ltd - recombinant human erythropoietin - תמיסה להזרקה - recombinant human erythropoietin 3000 iu / 0.3 ml - erythropoietin
ישראל -
עברית -
Ministry of Health
פרגבלין טבע 100 מג
teva israel ltd - pregabalin - קפסולות - pregabalin 100 mg - pregabalin
ישראל -
עברית -
Ministry of Health
פרגבלין טבע 150 מג
teva israel ltd - pregabalin - קפסולות - pregabalin 150 mg - pregabalin
ישראל -
עברית -
Ministry of Health
פרגבלין טבע 200 מג
teva israel ltd - pregabalin - קפסולות - pregabalin 200 mg - pregabalin
ישראל -
עברית -
Ministry of Health
פרגבלין טבע 225 מג
teva israel ltd - pregabalin - קפסולות - pregabalin 225 mg - pregabalin
ישראל -
עברית -
Ministry of Health
פרגבלין טבע 25 מג
teva israel ltd - pregabalin - קפסולות - pregabalin 25 mg - pregabalin
ישראל -
עברית -
Ministry of Health
פרגבלין טבע 300 מג
teva israel ltd - pregabalin - קפסולות - pregabalin 300 mg - pregabalin
ישראל -
עברית -
Ministry of Health
פרגבלין טבע 50 מג
teva israel ltd - pregabalin - קפסולות - pregabalin 50 mg - pregabalin
ישראל -
עברית -
Ministry of Health
פרגבלין טבע 75 מג
teva israel ltd - pregabalin - קפסולות - pregabalin 75 mg - pregabalin
ישראל -
עברית -
Ministry of Health
בינוקריט 40000 יחבל 1 מל
novartis israel ltd - epoetin alfa - תמיסה להזרקה - epoetin alfa 40000 iu / 1 ml - erythropoietin - erythropoietin - treatment of symptomatic anaemia associated with chronic renal failure (crf) in adult and paediatric patients:- treatment of anaemia associated with chronic renal failure in paediatric and adult patients on haemodialysis and adult patients on peritoneal dialysis.- treatment of severe anaemia of renal origin accompanied by clinical symptoms in adult patients with renal insufficiency not yet undergoing dialysis. treatment of anaemia and reduction of transfusion requirements in adult patients receiving chemotherapy for solid tumours, malignant lymphoma or multiple myeloma, and at risk of transfusion as assessed by the patient's general status (e.g. cardiovascular status, pre existing anaemia at the start of chemotherapy). binocrit can be used to increase the yield of autologous blood from patients in a predonation programme. its use in this indication must be balanced against the reported risk of thromboembolic events. treatment should only be given to non-iron deficient patients with moderate anaemia (haemoglob